Today, Coloplast is announcing changes to the company’s Executive Leadership Team (ELT). The changes relate to the company’s Interventional Urology business as well as the global People & Culture ...
The Coloplast Board of Directors are making changes to the Executive Leadership Team (ELT) to support the successful execution of the new Coloplast Group strategy. Over the last couple of months, ...
Coloplast's growth momentum and margins are declining, with recent operational missteps and weak demand, especially in China, weighing on results. Despite a strong market position and defensive ...
Coloplast is a global leader in specialized intimate healthcare, with strong innovation, high margins, and a defensible moat in core segments. Despite a 20% share price drop, I see upside potential, ...
On Thursday, HSBC (LON:HSBA) analysts revised their stance on Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY), downgrading the stock rating from Buy to Hold and adjusting the price target to DKK 670 ...
On Monday, Barclays analysts downgraded Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY) stock rating from Overweight to Equalweight and reduced the price target to DKK750.00 from DKK1,010.00. The ...
Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...
On Monday, RBC Capital Markets analyst Jack Reynolds-Clark revised the rating for Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY), elevating it from Sector Perform to Outperform. Accompanying this ...
The new 5-year strategy, Impact4, will be presented today at the company's Capital Markets Day 2025 The Impact4 strategy puts customers at the centre of everything we do and sets an ambitious goal for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results